|
|
|
| |
 |
Alain J. Gilbert
Co-Chairman - Paris & New York - alain[a]bionest.com |
Before co-founding Bionest in 2003, Alain was European President of Biogen, where he was responsible for the launch of Avonex ®, a biotech breakthrough treatment for MS. He held several positions at the senior management level such as European founder of IDEXX Labs Inc. (IDXX), involved in veterinary diagnostic, water and food contaminant testing products, and President of Medtronic Europe, world leader in cardiovascular devices (pacemakers, valves, etc.).
Alain started his career in sales and marketing at Abbott's Diagnostic Division and remained there for 17 years, holding key executive positions in the US and in Europe. At Bionest, Alain is mostly involved in Biopharmaceutical, Animal Health, Product Launch, Clinical Development Strategy and Private Equity, all with a primary focus on the US. |
|
| |
 |
Bob J. Easton
Co-Chairman - New York - reaston[a]bionest.com |
For over 25 years, Bob Easton has been recognized as a leader in healthcare business consulting. He has built and led two top firms, beginning with the founding of The Wilkerson Group in 1985. He has led scores of market development and strategic advisory assignments for clients, including large and specialty pharmaceutical companies, early-stage through publicly traded biopharmaceutical companies, and diagnostics businesses. He has influenced the decision-making of numerous healthcare professionals and supported hundreds of clients executives in Australia, Japan, Canada, U.S., Europe ans Israel. His interest in healthcare began when he managed a medical diagnostics business for Union Carbide.
Over a long career, Bob Easton has been highly visible in the industry, having written and spoken about multiple industry issues in scores of venues. He is Chairman-Elect of the New York Biotechnology Association (NYBA), after having served as Director. He has served on eight medical company Boards including Apex Bioventures, CollaGenex, and Cepheid. Bob Esaton holds two degrees in Chemical Engineering from Rice University and an MBA from the Harvard Business School. |
|
| |
 |
Olivier Lesueur
Managing Director - New York & Paris - olesueur[a]bionest.com |
| Jioned Bionest in 2004 and moved to the New York office in 2008 to develop US operations. Gained significant experience in strategic planning (franchise and product), commercialization strategy (US and ex-US), portfolio management and strategic due diligence. Before Bionest, Olivier was a consultant at Celerant Consulting. Olivier has an MS in Management from EM-Lyon Business School and an MS in Molecular Biology from Polytech Clermont-Ferrand. |
|
| |
 |
Sean X. Hu
Managing Director, New York - shu[a]bionest.com |
| Sean is mainly involved with North American clients on broad strategic issues, and is a thought leader in personalized medicine strategy. Sean brings 17 years of rich experience in life sciences consulting, industries and academia, including over 6 years at major strategy consulting firms, augmented by hands-on industry experience across multiple functional areas at Illumina, BMS and CuraGen. He holds a PhD from NYU, and an MBA from Wharton. |
|
| |
 |
Mary Koto
Managing Director, San Diego - mkoto[a]bionest.com |
| Mary has more than 25 years of healthcare experience in both operating companies and in consulting. Prior ton joining Bionest, she was a founding partner at Scisive Consulting where she worked on strategy assignments in a broad range of therapeutic areas. Prior to that, she worked +17 years in marketing and strategic planning in pharmaceutical and medical device companies including Agouron Pharmaceuticals and Gensia Sicor, launching products in hospitals and physician offices. Mary has a PhD from Yale University and an MBA from Stanford. |
|
| |
 |
Catharine Staughton
Managing Director, London - cstaughton[a]bionest.com |
| Catharine's consulting career began at The Wilkerson Group (later part of IBM Consulting) in 1993 and she has led numerous strategy and marketing projects for clients across the globe. Before then she worked in business development in the pharmaceutical industry and as a financial analyst forecasting new product sales. Catharine has substancial project experience in a wide range of medical products. Catharine graduated in Natural Sciences (Genetics) from the University of Cambridge and has an MBA from INSEAD in France. She speaks excellent French. |
|
|
|
